H. pylori Eradication Duration
The recommended duration for H. pylori eradication therapy is 14 days for all first-line regimens, as this achieves significantly higher eradication rates compared to shorter durations.
Treatment Duration by Regimen Type
First-Line Therapy Duration
All major international guidelines (Toronto Consensus, Maastricht V/Florence, and American College of Gastroenterology) converge on 14 days as the optimal duration for first-line H. pylori eradication therapy 1, 2. This recommendation is based on the principle that succeeding on the first attempt is paramount to avoid retreatment, reduce costs, minimize patient anxiety, and prevent disruption of gut microbiota 1.
Specific regimen durations:
- Bismuth quadruple therapy (PBMT): 14 days preferred, though 10-14 days acceptable if 10 days proven locally effective 1
- Concomitant quadruple therapy (PAMC): 14 days preferred, 10-14 days acceptable 1
- PPI triple therapy (clarithromycin-based): 14 days mandatory 1
- Levofloxacin triple therapy: 14 days preferred, 10-14 days acceptable 1
Evidence Supporting 14-Day Duration
A comprehensive Cochrane meta-analysis of 75 studies demonstrated that increasing PPI triple therapy from 7 to 14 days significantly improved eradication rates from 72.9% to 81.9% (RR 0.66, NNT = 11) 3. The benefit was particularly pronounced for PPI + clarithromycin + amoxicillin regimens, where 14 days achieved superior results compared to both 7 days (RR 0.65) and 10 days (RR 0.69) 3.
Real-world Canadian data confirmed these findings, showing 85% eradication with 14-day therapy versus only 70% with 7-day therapy (P≤0.001), with treatment duration being an independent predictor of success 4.
Rescue Therapy Duration
For patients who fail initial therapy 5:
- Bismuth quadruple therapy: 14 days 5
- Levofloxacin-based therapy: 10-14 days 5
- High-dose dual therapy: 14 days 1
- Rifabutin triple therapy: 10 days 5, 1
Clinical Reasoning
The shift to 14-day therapy addresses the global problem of declining eradication rates due to increasing antibiotic resistance, particularly to clarithromycin (now >30% in many regions) 6. The Toronto Consensus specifically emphasizes that 14 days should be standard for all first-line treatments to provide simplicity for clinicians and maximize first-attempt success 2.
Important Caveats
Adverse events: While 14-day therapy shows marginally increased adverse events compared to 7-day therapy (19.4% vs 15.5%, NNTH = 31), discontinuation rates due to side effects remain similar across durations 3. The modest increase in side effects is outweighed by the substantial improvement in eradication rates.
Regional variations: The ACG allows 10-14 days for certain quadruple therapies in the absence of U.S.-specific data showing superiority of 14 days 1, but the international consensus strongly favors 14 days unless local data demonstrates equivalent efficacy with shorter courses 1.
Resistance patterns: In areas with high dual resistance to clarithromycin and metronidazole, bismuth quadruple therapy for 14 days is particularly favored as it maintains acceptable success even with metronidazole resistance 1.